Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of withdrawing amifampridine phosphate treatment from
patients with LEMS. One half of the patients will continue to receive amifampridine phosphate
and the other half will receive placebo, during this double-blind study.